Business Context and Reporting Period
This Form 8-K, dated January 17, 2024, reports on TenX Keane Acquisition (the "Company"), a Cayman Islands-based special purpose acquisition company (SPAC). The filing details the results of an extraordinary general meeting held on January 17, 2024, regarding the extension of the Company's deadline to consummate a business combination with Citius Oncology, Inc. (via Citius Pharmaceuticals, Inc.).
Key Financial Metrics and Liquidity
- Share Redemptions: 2,287,923 ordinary shares were tendered for redemption at approximately $10.90 per share, totaling approximately $24.9 million removed from the Trust Account.
- Remaining Capitalization: Following redemptions, 6,653,077 ordinary shares remain outstanding.
- Extension Contribution: The Sponsor (designated as Citius Pharma) deposited $200,000 into the Trust Account as a loan to fund the first extension period.
- Debt: The Company issued a non-interest-bearing promissory note with a principal amount of $200,000 to Citius Pharma, repayable per the terms of the Merger Agreement.
- Revenue/Profit: The filing does not provide revenue, profit, or operating margin data as the Company is a pre-combination SPAC.
Material Changes Versus Prior Period
- Extension of Liquidation Date: The Company's liquidation date has been extended from January 18, 2024, to April 18, 2024. The Articles of Association were amended to allow for up to eight total extensions (one 3-month extension followed by seven 1-month extensions) through November 18, 2024.
- Trust Account Reduction: The Trust Account balance decreased by approximately $24.9 million due to shareholder redemptions.
- Corporate Governance: Shareholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
- Business Combination Status: The Company is proceeding with the merger with Citius Oncology, Inc., having secured shareholder approval for the necessary time extension.
- Future Funding Requirements: If additional extensions are required beyond April 18, 2024, the Sponsor must contribute the lesser of $66,667 or $0.03 per non-redeemed share for each subsequent one-month extension.
- Risks: The filing includes standard forward-looking statement disclaimers regarding the risks and uncertainties that may cause actual results to differ from expectations, specifically concerning the completion of the business combination.
Investor Verification Checklist
- Verify the final Trust Account balance after the $24.9 million redemption withdrawal and the $200,000 contribution.
- Confirm the specific terms of the promissory note issued to Citius Pharma (Exhibit 10.1) regarding repayment conditions upon merger completion or failure.
- Review the Third Amended and Restated Memorandum and Articles of Association (Exhibit 3.1) for details on the mechanics of future monthly extensions.
- Monitor the Company's ability to meet Nasdaq continued listing requirements following the reduction in outstanding shares.